Sangamo Therapeutics - SGMO Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month target prices for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $5.00 to $19.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 95.3% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.

Sangamo Therapeutics' stock was trading at $7.50 on January 1st, 2022. Since then, SGMO shares have decreased by 31.7% and is now trading at $5.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our SGMO earnings forecast.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The biopharmaceutical company earned $29.38 million during the quarter, compared to analyst estimates of $24.63 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 48.06% and a negative net margin of 150.96%. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.33) earnings per share.

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (4.94%), Credit Suisse AG (2.42%), JPMorgan Chase & Co. (0.96%), Goldman Sachs Group Inc. (0.93%), Renaissance Technologies LLC (0.92%) and Millennium Management LLC (0.77%). Insiders that own company stock include Biogen Inc, Gary Loeb, H Stewart Parker, John Markels, Joseph S Zakrzewski, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends.

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGMO stock can currently be purchased for approximately $5.12.

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $801.54 million and generates $110.70 million in revenue each year. The biopharmaceutical company earns $-178,290,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The company employs 431 workers across the globe.

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.